DNA-microarray analysis of brain cancer: Molecular classification for therapy

Nature Reviews Neuroscience

Volumn 5, Issue 10, 2004, Pages 782-792

  Mischel, Paul S ^a   Cloughesy, Timothy F ^a   Nelson, Stanley F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GEFITINIB; IMATINIB;

BRAIN CANCER; BRAIN TUMOR; CANCER CLASSIFICATION; CANCER THERAPY; DNA MICROARRAY; DRUG SCREENING; DRUG TARGETING; GENE EXPRESSION; HUMAN; LETHALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE;

ANIMALS; BRAIN NEOPLASMS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; GLIOMA; HUMANS; MEDULLOBLASTOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 5044224775     PISSN: 1471003X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrn1518     Document Type: Review

References (101)

1. Slonim, D. K. From patterns to pathways: gene expression data analysis comes of age. Nature Genet. 32 (Suppl.), 502-508 (2002).
2. Barabasi, A. L. & Oltvai, Z. N. Network biology: understanding the cell's functional organization. Nature Rev. Genet. 5, 101-113 (2004). This paper is an excellent review of the concept of network biology, and describes the quantitative tools that can be used to analyse networks.
3. Ideker, T. Systems biology 101 - what you need to know. Nature Biotechnol. 22, 473-475 (2004).
4. Legier, J. M. et al, RESPONSE: re: brain and other central nervous system cancers: recent trends in incidence and mortality. J. Natl Cancer Inst. 92, 77-78 (2000).
5. Mischel, P. S. & Cloughesy, T. F. Targeted molecular therapy of GBM. Brain Patrol. 13, 52-61 (2003).
6. Bailey, P. & Gushing, H. A Classification of the Tumors of the Glioma Group on a Histogenic Basis with a Correlated Study of Prognosis (Lippincott, Philadelphia, 1928).
7. Lu, Q. R. et al. Common developmental requirement for Olig function indicates a motor neuron/oligodendrocyte connection. Cell 109, 75-86 (2002).
8. Doetsch, F. The glial identity of neural stem cells. Nature Neurosci. 6, 1127-1134 (2003).
9. Doetsch, F, Caille, I., Lim, D. A., Garcia-Verdugo, J. M. & Alvarez-Buylla, A. Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell 97, 703-716 (1999).
10. Zhou, Q. & Anderson, D. J. The bHLH transcription factors OLIG2 and OLIG1 couple neuronal and glial subtype specification. Cell 109, 61-73 (2002).
11. Hemmati, H. D. et al. Cancerous stem cells can arise from pediatric brain tumors. Proc. Natl Acad. Sci. USA 100, 15178-15183 (2003).
12. Bachoo, R. M. et al. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 1, 269-277 (2002).
13. Kleihues, P. et al. The WHO classification of tumors of the nervous system. J. Neuropathol. Exp. Neurol. 61, 215-225 (2002).
14. Holland, E. C. et al. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nature Genet 25, 55-57 (2000).
15. Lee, Y. & McKinnon, P. J, DNA ligase IV suppresses medulloblastoma formation. Cancer Res. 62, 6395-6399 (2002). In this paper, the authors compare the global gene-expression profiles of medulloblastomas that are derived from a set of genetically defined mouse crosses, thereby identifying the contribution of a number of genes, including PTC1, LIG4 and p53, in the development of medulloblastoma.
16. Lee, Y. et al. A molecular fingerprint for medulloblastoma. Cancer Res. 63, 5428-5437 (2003).
17. Weiner, H. L. et al. Induction of medulloblastomas in mice by sonic hedgehog, independent of Gli 1. Cancer Res. 62, 6385-6389 (2002).
18. Rao, G., Pedone, C. A., Coffin, C. M., Holland, E. C. & Fults, D. W. c-Myc enhances sonic hedgehog-induced medulloblastoma formation from nestin-expressing neural progenitors in mice. Neoplasia 5, 198-204 (2003).
19. Rao, G. et al. Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice. Oncogens 23, 6156-6162 (2004).
20. Choe, G. et al. Analysis of the phosphatidylinostol 3́-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. 63, 2742-2746 (2003).
21. Ermoian, R. P. et al. Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival. Clin. Cancer Res. 8, 1100-1106 (2002).
22. Vivanco, I. & Sawyers, C. L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nature Rev. Cancer 2, 489-501 (2002).
23. Berman, D. M. et al. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 297, 1559-1561 (2002). This paper was crucial in defining the role of the hedgehog pathway in the genesis of medulloblastoma, and in identifying inhibition of the hedgehog pathway as a potential therapy.
24. Wechsler-Reya, R. & Scott, M. P. The developmental biology of brain tumors. Annu. Rev. Neurosci. 24, 385-428 (2001). This outstanding review highlights the genetic mechanisms that are known to be involved in medulloblastoma, as well as other paediatric brain tumours.
25. Ramaswamy S. Translating cancer genomes into clinical oncology. N. Engl. J. Med. 350, 1814-1816 (2004).
26. Liotta, L. A. et al. Protein microarrays: meeting analytical chalenges for clinical applications. Cancer Cell 3, 317-325 (2003).
27. Lindblad-Toh, K. et al. Loss-of-heterozygosity analysis of small-cell lung carcinomas using single-nucleotide polymorphism arrays. Nature Biotechnol, 18, 1001-1005 (2000).
28. Hoque, M. O., Lee, C. C., Cairns, P., Schoenberg, M. & Sidransky, D. Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatelite analysis. Cancer Res. 63, 2216-2222 (2003).
29. Albertson, D. G. & Pinkel, D. Genomic microarrays in human genetic disease and cancer. Hum. Mol. Genet. 12, R145-R152 (2003).
30. Shi, H. et al. Triple analysis of the cancer epigenome: an integrated microarray system for assessing gene expression, DNA methylation, and histone acetylation. Cancer Res. 63, 2164-2171 (2003).
31. Yeakley, J. M. et al. Profiling aternative splicing on fiber-optic arrays. Nature Biotechnol. 20, 353-358 (2002).
32. Mischel, P. S., Nelson, S. F. & Cloughesy, T. F. Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy. Cancer Biol. Ther. 2, 242-247 (2003). This review provides an overview of the gene-expression and signal-transduction alterations in glioblastoma and suggests potential therapeutic strategies.
33. Druker, B. J. Perspectives on the development of a molecularly targeted agent. Cancer Cell 1, 31-36 (2002).
34. Sawyers, C. L. Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics. Cancer Cell 1, 13-15 (2002).
35. Betensky, R. A., Louis, D. N. & Cairncross, J. G. Influence of unrecognized molecular heterogeneity on randomized clinical trials. J. Clin. Oncol. 20, 2495-2499 (2002).
36. Bianco, R. et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibtors. Oncogene 22, 2812-2822 (2003).
37. Golub, T. R. et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286, 531-537 (1999).
38. Armstrong, S. A. et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nature Genet 30, 41-47 (2002).
39. Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
40. Sorlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869-10874 (2001).
41. Sorlie, T. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 100, 8418-8423 (2003).
42. Ramaswamy, S. et al. Multiclass cancer diagnosis using tumor gene expression signatures. Proc. Natl Acad. Sci. USA 98, 15149-15154 (2001).
43. Shia, J. et al. Value of histopathology in predicting microsatelite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer. Am. J. Surg. Pathol. 27, 1407-1417 (2003).
44. Cardiff, R. D. et al. Validation: the new challenge for pathology. Toxicol. Pathol. 32, 31-39 (2004).
45. Boorman, G. A. et al. Toxicogenomics, drug discovery, and the pathologist. Toxicol. Pathol. 30, 15-27 (2002).
46. Dhanasekaran, S. M. et al. Delineation of prognostic biomarkers in prostate cancer. Nature 412, 822-826 (2001).
47. Shappell, S. B. et al. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res. 64, 2270-2305 (2004).
48. Lossos, I. S. et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N. Engl. J. Med. 350, 1828-1837 (2004).
49. Bullinger, L. et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N. Engl. J. Med. 350, 1605-1616 (2004).
50. Valk, P. J. et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N. Engl. J. Med. 350, 1617-1628 (2004).
51. Rosenwald, A. et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 1937-1947 (2002).
52. Glinsky, G. V., Higashiyama, T. & Glinskii, A. B. Classification of human breast cancer using gene expression profiling as a component of the survival predictor algorithm, Clin. Cancer Res. 10, 2272-2283 (2004).
53. Glinsky, G. V., Glinskii, A. B., Stephenson, A. J., Hoffman, R. M. & Gerald, W. L. Gene expression profiling predicts clinical outcome of prostate cancer. J. Clin. Invest. 113, 913-923 (2004).
54. Hedenfalk, I. et al. Molecular classification of familial non-BRCA1/BRCA2 breast cancer. Proc. Natl Acad. Sci. USA 100, 2532-2537 (2003).
55. van de Vijver, M. J. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002).
56. Lapointe, J. et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc. Natl Acad. Sci. USA 101, 811-816 (2004).
57. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004).
58. Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
59. Pomeroy, S. L. et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415, 43-442 (2002). This important paper showed that medulloblastomas can be readily distinguished from other brain tumours, including morphological mimics, on the basis of gene-expression profiling. It also showed that a relatively small number of genes could accurately predict patient survival and response to therapy.
60. Fernandez-Teijeiro, A. et al. Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas. J. Clin. Oncol. 22, 994-998 (2004). In a logical continuation of the work described in reference 59, the authors showed that gene-expression data can predict the outcome for patients with medulloblastoma, independent of clinical variables.
61. MacDonald, T. J. et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nature Genet 29, 143-152 (2001). In this paper, the authors used cDNA-microarray analysis to identify a potentially crucial and therapeutically targetable pathway that might promote metastasis in medulloblastoma.
62. Oliver, T. G. et al. Transcriptional profiling of the sonic hedgehog response: a critical role for N-myc in proliferation of neuronal precursors. Proc. Natl Acad. Sci. USA 100, 7331-7336 (2003).
63. Shai, R. et al. Gene expression profiling identifies molecular subtypes of gliomas. Oncogene 22, 4918-2493 (2003).
64. Rickman, D. S. et al. Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res. 61, 6885-6891 (2001).
65. Salinen, S. L. et al. Identification of deferentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res. 60, 6617-6622 (2000).
66. Huang, H. et al. Gene expression profiling of low-grade diffuse astrocytomas by cDNA arrays. Cancer Res. 60, 6868-6874 (2000).
67. Fuller, G. N. et al. Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling. Cancer Res. 59, 4228-4232 (1999).
68. Godard, S. et al. Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res. 63, 6613-6625 (2003).
69. Khatua, S. et al. Overexpression of the EGFR/FKBP12/HIF-2α pathway identified in childhood astrocytomas by angiogenesis gene profiling. Cancer Res. 63, 1865-1870 (2003).
70. Nutt, C. L. et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res. 63, 1602-1607 (2003). This paper showed that cDNA-microarray technology could potentially be used to address diagnostically confusing gliomas, and that transcriptional information contains more data about outcome than does pathological examination.
71. Mischel, P. S. et al. Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene 22, 2361-2373 (2003). This paper highlights the potential of cDNA microarrays to detect molecular subsets of morphologically identical glioblastomas.
72. Freije, W. A. et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res. [In the press]. In this paper, the authors demonstrate that gene-expression-based grouping of malignant gliomas is a more powerful predictor of survival than pathological type, grade or age.
73. Schert, U. et al. A gene expression database for the molecular pharmacology of cancer. Nature Genet. 24, 236-244 (2000).
74. Staunton, J. E. et al. Chemosensitivity prediction by transcriptional profiling. Proc. Natl Acad. Sci. USA 98, 10787-10792 (2001).
75. Wallqvist, A. et al. Mining the NCI screening database: explorations of agents involved in cell cycle regulation. Prog. Cell Cycle Res. 5, 173-179 (2003).
76. Butte, A. J., Tamayo, P., Slonim, D., Golub, T. R. & Kohane, I. S. Discovering functional relationships between RNA expression and chemotherapeutic susceptibility using relevance networks. Proc. Natl Acad. Sci. USA 97, 12182-12186 (2000).
77. Bohen, S. P. et al. Variation in gene expression patterns in follicular lymphoma and the response to rituximab. Proc. Natl Acad. Sci. USA 100, 1926-1930 (2003).
78. Sotiriou, C. et al. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res. 4, R3 (2002).
79. Cheok, M. H. et al. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nature Genet 34, 85-90 (2003).
80. Stegmaier, K. et al. Gene expression-based high-throughput screening (GE-HTS) and application to leukemia differentiation. Nature Genet. 36, 257-263 (2004).
81. Reifenberger, G. & Louis, D. N. Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J. Neuropathol. Exp. Neurol. 62, 111-126 (2003).
82. Gajjar, A. et al. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J. Clin. Oncol. 22, 984-993 (2004).
83. Liu E. T. & Karuturi, K. R. Micro-arrays and clinical investigations. N. Engl. J. Med. 350, 1595-1597 (2004).
84. Diehn, M., Eisen, M. B., Botstein, D. & Brown, P. O. Large-scale identification of secreted and membrane-associated gene products using DNA microarrays. Nature Genet. 25, 58-62 (2000).
85. Tanwar, M. K., Gilbert, M. R. & Holland, E. C. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res. 62, 4364-4368 (2002).
86. Herschman, H. R. Molecular imaging: looking at problems, seeing solutions. Science 302, 605-608 (2003).
87. Bergmann, S., Ihmels, J. & Barkai, N. Similarities and differences in genome-wide expression data of six organisms. PLoS Biol. 2, E9 (2004).
88. Stuart, J. M., Sega, E., Koller, D. & Kim, S. K. A gene-coexpression network for global discovery of conserved genetic modules. Science 302, 249-255 (2003).
89. Chang, H. Y. et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol. 2, E7 (2004).
90. Whitfield, M. L. et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol. Biol. Cell 13, 1977-2000 (2002).
91. Ficenec, D. et al. Computational knowledge integration in biopharmaceutical research. Brief. Bioinform. 4, 260-278 (2003).
92. Buckingham, S. Bioinformatics: programmed for success. Nature 425, 209-215 (2003).
93. Shannon, R et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498-2504 (2003).
94. Angelastro, J. M. et al. Identification of diverse nerve growth factor-regulated genes by serial analysis of gene expression (SAGE) profiling. Proc. Natl Acad. Sci. USA 97, 10424-10429 (2000).
95. Liu, D. X. & Greene, L. A. Regulation of neuronal survival and death by E2F-dependent gene repression and derepression. Neuron 32, 425-438 (2001).
96. Hartwell, L. H., Hopfield, J. J., Leibler, S. & Murray, A. W. From molecular to modular cell biology. Nature 402 (Suppl.), C47-C52 (1999).
97. Jeong, H., Tombor, B., Albert, R., Oltvai, Z. N. & Barabasi, A. L. The large-scale organization of metabolic networks. Nature 407, 651-654 (2000).
98. Alon, U. Biological networks: the tinkerer as an engineer. Science 301, 1866-1867 (2003).
99. Agrawal, H. Extreme self-organization in networks constructed from gene expression data. Phys. Rev. Lett. 89, 268702 (2002).
100. Chen, J. et al. The PEPR GeneChip data warehouse, and implementation of a dynamic time series query tod (SGQT) with graphical interface. Nucleic Acids Res. 32, D578-D581 (2004).
101. Ramaswamy, S. & Golub, T. R. DNA microarrays in clinical oncology. J. Clin. Oncol. 20, 1932-1941 (2002).